Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.
Patients with cancer experience a host of behavioral alterations that include depression, fatigue, sleep disturbances, and cognitive dysfunction. These behavioral comorbidities are apparent throughout the process of diagnosis and treatment for cancer and can persist well into the survivorship period. There is a rich literature describing potential consequences of behavioral comorbidities in patients with cancer including impaired quality of life, reduced treatment adherence, and increased disease-related morbidity and mortality. Medical complications of cancer and its treatment such as anemia, thyroid dysfunction, and the neurotoxicity of cancer chemotherapeutic agents account in part for these behavioral changes. Nevertheless, recent advances in the neurosciences and immunology/oncology have revealed novel insights into additional pathophysiologic mechanisms that may significantly contribute to the development of cancer-related behavioral changes. Special attention has been focused on immunologic processes, specifically activation of innate immune inflammatory responses and their regulation by neuroendocrine pathways, which, in turn, influence CNS functions including neurotransmitter metabolism, neuropeptide function, sleep-wake cycles, regional brain activity, and, ultimately, behavior. Further understanding of these immunologic influences on the brain provides a novel conceptual framework for integrating the wide spectrum of behavioral alterations that occur in cancer patients and may reveal a more focused array of translational targets for therapeutic interventions and future research. Such developments warrant complementary advances in identification of cancer patients at risk as well as those currently suffering, including an increased emphasis on the status of behavior as a "sixth vital sign" to be assessed in all cancer patients throughout their disease encounter.
Miller
Andrew H
AH
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Winship Cancer Institute, 1365-C Clifton Rd, 5th Floor, Atlanta, GA 30322, USA. amill02@emory.edu
Ancoli-Israel
Sonia
S
Bower
Julienne E
JE
Capuron
Lucile
L
Irwin
Michael R
MR
D000818:Animals; D015415:Biomarkers / Q000097:blood; D019454:Chronotherapy / Q000379:methods; D002940:Circadian Rhythm; D003071:Cognition / Q000187:drug effects; D003072:Cognition Disorders / Q000209:etiology / Q000378:metabolism; D015897:Comorbidity; D016207:Cytokines / Q000009:adverse effects / Q000378:metabolism*; D003863:Depression / Q000209:etiology; D005221:Fatigue / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007249:Inflammation / Q000378:metabolism* / Q000523:psychology*; D009369:Neoplasms / Q000150:complications* / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D009483:Neuropsychological Tests; D009490:Neurosecretory Systems / Q000378:metabolism*; D012893:Sleep Wake Disorders / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D013315:Stress, Psychological / Q000209:etiology / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000378:metabolism*
D015415:Biomarkers; D016207:Cytokines; D006854:Hydrocortisone